Skip to main
STOK

STOK Stock Forecast & Price Target

STOK Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 22%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Stoke Therapeutics is on track to become a leading player in the biotechnology industry with its innovative TANGO technology and promising drug pipeline targeting haploinsufficiency diseases. With positive data from its first medicine in development and ongoing clinical trials for various genetic diseases, Stoke is positioned for long-term success. Additionally, the company's strong financials and partnerships add further potential for future growth and value creation.

Bears say

Stoke Therapeutics is a biotechnology company with a potentially promising treatment for Dravet syndrome, but their management's decision to wait for full P3 data before offering the drug to patients and payors is concerning. While the OLE data from year four shows positive results for non-seizure symptoms, the main question is what other disease modifications the P3 EMPEROR trial will support. Additionally, the company faces multiple risks, including stock price volatility and intellectual property risks. With a need to raise capital before becoming profitable, there is potential for share dilution for shareholders.

STOK has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 22% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Stoke Therapeutics Inc (STOK) Forecast

Analysts have given STOK a Strong Buy based on their latest research and market trends.

According to 9 analysts, STOK has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $39.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $39.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Stoke Therapeutics Inc (STOK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.